On the basis of results of the most recent CVOTs (DAPA-HF, DAPA-CKD, EMPEROR-R), the FDA has approved dapagliflozin (2020) and empagliflozin (2021) to reduce risk for CV death and HF hospitalization in adults with HF and reduced ejection fraction regardless of whether they have diabetes [24, 25]
doi:10.1006/bbrc.2000.4212 170
Follow her on Instagram @daniellesinay.
Patients should seek immediate medical attention if they experience severe, persistent abdominal pain, particularly if radiating to the back, accompanied by nausea and vomiting
For the right patient, medications such as semaglutide and tirzepatide may be useful tools when they are prescribed, monitored, and adjusted as part of a physician-guided plan